World News | Pfizer Looks at Vaccine with Fewest Side Effects
Get latest articles and stories on World at LatestLY. Pfizer and its German partner BioNTech will take its COVID-19 vaccine candidate with the fewest side effects into final-stage testing.
New York, Aug 20 (AP) Pfizer and its German partner BioNTech will take its COVID-19 vaccine candidate with the fewest side effects into final-stage testing.
In an online report Thursday, Pfizer researchers compared data from early-stage testing of two vaccine candidates. Both revved immune systems similarly, and neither caused severe side effects.
Also Read | France Opens Visa Service For Indian Students And Researchers.
But one candidate caused considerably fewer injection reactions, particularly in older adults -- symptoms such as fever, headache, chills or muscle pain that are temporary but unpleasant, Pfizer reported.
Final testing of Pfizer's lead candidate has begun as researchers recruit about 30,000 people in the US and other countries. It's one of a handful of experimental vaccines to reach end-stage tests around the world.
Also Read | 5th World Conference of Speakers of Parliament: India Asks International Community to Isolate Pakistan.
It generally takes years to develop a safe and effective vaccine for widespread use and distribution. US health officials hope to start offering vaccinations sometime next year. (AP)
(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)